8-羟基喹啉离子载体对多重耐药肠球菌和金黄色葡萄球菌的新抗菌活性
本研究合成并表征了一种8-羟基喹啉基离子载体抗生素「IP-抗生素12」,针对多重耐药屎肠球菌和金黄色葡萄球菌进行体外及小鼠体内评估。体外显示其具有杀菌活性、低耐药倾向、可增加部分菌株对特定抗生素的敏感性、毒性特征良好并扰乱细菌金属稳态。IP-抗生素12对多重耐药金黄色葡萄球菌皮肤感染有治疗效力,但对小鼠全身和肺部感染模型无效。
要点
- IP-抗生素12对多重耐药屎肠球菌和金黄色葡萄球菌有体外杀菌活性。
- IP-抗生素12作为外用抗菌药或与口服利奈唑胺联用对皮肤感染有效。
- IP-抗生素12对小鼠全身和肺部感染模型无效。
核心结论
- IP-抗生素12对多重耐药革兰阳性菌有潜在治疗价值,并为开发体内疗效更强的下一代IP-抗生素奠定基础。
研究设计与样本
- 研究合成并表征了8-羟基喹啉基离子载体抗生素「IP-抗生素12」,使用多重耐药屎肠球菌和金黄色葡萄球菌菌株进行体外研究,并在小鼠感染模型中评估疗效。
主要发现
- IP-抗生素12对多重耐药屎肠球菌和金黄色葡萄球菌展现杀菌活性,耐药出现倾向低。
- IP-抗生素12增加部分菌株对特定抗生素的敏感性,毒性特征良好,并扰乱细菌金属稳态。
- IP-抗生素12对多重耐药金黄色葡萄球菌皮肤感染有治疗效力,作为直接作用的外用抗菌药及与口服利奈唑胺联用时的抗生素辅助剂。
- IP-抗生素12在小鼠全身和肺部感染模型中无效。
临床怎么用
- 提示IP-抗生素12可能作为外用抗菌药或抗生素辅助剂用于多重耐药革兰阳性菌皮肤感染,但全身和肺部感染不适用。
局限性
- IP-抗生素12在小鼠全身和肺部感染模型中未显示疗效,体内治疗效力有待增强。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Enterococcus faecium and Staphylococcus aureus are opportunistic bacterial pathogens with a demonstrated capacity to develop antimicrobial resistance and cause serious life-threatening infections, underscoring the urgent need for new therapeutic options. METHODS: Here, we have synthesized and characterized the activities of an 8-hydroxyquinoline-based ionophore antibiotic (ionophoroantibiotic; IP antibiotic), designated 'IP-antibiotic 12.' RESULTS: Using multidrug-resistant strains of E. faecium and S. aureus, in vitro investigations revealed that IP-antibiotic 12 exhibits bactericidal activity, demonstrates a low propensity for resistance emergence, increases the susceptibility of particular strains to select antibiotics, possesses a favorable toxicity profile, and dysregulates bacterial metal homeostasis. IP-antibiotic 12 demonstrated therapeutic efficacy against multidrug-resistant S. aureus skin infection, as a direct-acting topical antimicrobial and antibiotic adjunct when co-administered with oral linezolid. Interestingly, it was not efficacious in murine models of systemic and pulmonary infection. CONCLUSIONS: These results highlight the potential of IP-antibiotic 12 as a novel therapeutic against multidrug-resistant gram-positive bacteria and provide a foundation for the development of next-generation IP-antibiotics with enhanced in vivo therapeutic efficacy.
引用
- Li G, El-Deeb IM, Whyte HG, et al. Newly identified antimicrobial activity of an 8-hydroxyquinoline-based ionophore against multidrug-resistant Enterococcus faecium and Staphylococcus aureus. J Antimicrob Chemother. 2026. PMID: 42235930. doi:10.1093/jac/dkag186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。